Even more surprising is that the COAST‘ second endpoint...

Even more surprising is that the COAST‘ second endpoint (anatomy) was not hit either, which is very unusual. Even in the only less sucessful DME trial where OPT-302 was combined with ELYEA, the second endpoint was hit.

“Retinal thickness measured by CST on spectral domain optical coherence tomography (SD-OCT), was reduced by -52.16 µm, from 436 µm atbaseline to 384 µm at week 12 following OPT-302 combination therapy. The mean CST was reduced by -34.92 µm, from 422 µm at baseline to 389 µm at week 12 in the Eylea control group”